Momentum Moments – Vive Crop Protection

Dive Brief: Verge Genomics, a biotechnology company using artificial intelligence to develop therapies for diseases of the nervous system, announced on Friday a four-year partnership with AstraZeneca’s rare disease unit Alexion to identify new drug targets. As part of the agreement, Verge will receive up to $42 million in upfront, equity and near-term payments. The company also could receive as mu